Resources
    Blog Post

    How Conventional Metrics Can Misrepresent Organoid Drug Sensitivity

    Patient-derived tumor organoids are increasingly used to evaluate drug sensitivity and identify effective cancer therapies. However, accurately quantifying their responses remains challenging because organoids can exhibit substantial differences in baseline growth rates and morphological changes. Experimental variability in initial seeding density can further confound these measurements.

    Conventional drug response metrics, including relative viability (RV), Normalized Growth Rate Inhibition (GR), and Normalized Drug Response (NDR), were originally developed for 2D cell cultures, where growth characteristics are generally more uniform and easier to quantify than in complex 3D organoid models. These metrics rely on assumptions that obscure differences in drug response when applied to organoids because of their different growth characteristics and sensitivity to seeding density, particularly for patient-derived models.

    To accurately quantify organoid drug responses, a metric should:

    1. Account for differences in initial seeding density by normalizing each well to its own baseline measurement.
    2. Correct for variations in growth rate to enable meaningful comparisons between fast- and slow-growing organoid models.
    3. Distinguish cytostatic from cytotoxic effects by measuring growth inhibition and loss of viable organoid material.

    To address these challenges, we developed the Normalized Organoid Growth Rate (NOGR), a drug-response metric specifically designed for live-imaging of organoids. In our study published in Communications Biology, we investigated 11 pancreatic cancer organoid models spanning four distinct morphological classes and a wide range of growth rate.

    Study design
    Developing and validating NOGR

    Live-cell imaging of pancreatic cancer organoids to compare GR, NDR, and NOGR.

    PDAC organoid models
    11
    PDAC organoid models
    chemotherapeutics
    5
    chemotherapeutics
    imaging timepoints
    3
    imaging timepoints
    well plate format
    384
    well plate format
    1. 10 hBaseline brightfield image
    2. 272 h and 120 hFollow-up brightfield images for longitudinal growth measurement
    3. 3Metric comparisonAssess RV, GR, NDR, and develop NOGR
    Study overview based on Deben et al. (2024).

    1. Why relative viability can misrepresent drug sensitivity

    RV is one of the most widely used metrics in organoid drug screening, typically calculated by comparing treated samples with untreated controls at a single timepoint. Although straightforward, RV is highly dependent on the proliferation rate of the untreated population, which can distort drug sensitivity measurements when comparing fast- and slow-growing organoid models. Variations in initial seeding density introduce further bias, as conventional endpoint measurements do not account for differences in the starting amount of viable organoid material. Moreover, RV does not distinguish between cytostatic and cytotoxic responses, as both reduced proliferation and cell death can produce similar measurements.

    To address these limitations, growth-rate-based metrics such as GR and NDR were developed. GR incorporates changes in cell growth relative to the initial measurement and untreated controls, reducing the influence of baseline proliferation rates on apparent drug sensitivity.3 NDR extends this approach by incorporating a positive cell-death control, enabling differentiation between growth inhibition and cytotoxicity.4

    In patient-derived pancreatic organoids, NDR improved discrimination of treatment responses compared with RV and GR (Figure 1), highlighting the importance of accounting for differences in growth rate and cytotoxicity when evaluating drug sensitivity across organoid models.

    Figure 1. Growth-rate normalization improves drug-response discrimination in patient-derived pancreatic cancer organoids. Dose-response curves for eight organoid models were treated with gemcitabine-paclitaxel and quantified using relative viability (RV), Normalized Growth Rate Inhibition (GR), and Normalized Drug Response (NDR). Image adapted from Figure 2 of Le Compte et al. (2023).

    2. Why conventional GR and NDR metrics are not enough

    Although GR and NDR improve upon RV, both metrics have limitations when applied to organoids with substantially different growth rates. GR normalizes drug-induced growth changes against untreated controls, reducing the influence of baseline proliferation rates. However, because GR does not incorporate a positive cell-death control, it can underestimate cytotoxic effects in fast-growing organoids (Figure 2A).

    NDR incorporates both untreated and positive cell-death controls to distinguish cytostatic from cytotoxic responses. However, its logarithmic normalization can distort drug-response measurements across models with different growth rates. In rapidly proliferating models, it can underestimate growth inhibition (Figure 2A), while in slow-growing organoids, it can exaggerate cytotoxic effects (Figure 2B).

    To address these limitations, we developed the NOGR, which normalizes changes in viable organoid area against untreated controls for positive growth and a positive death control for negative growth. This piecewise linear approach more accurately quantifies growth inhibition and cytotoxicity across different proliferation rates.

    We first demonstrated these differences using simulated responses representing slow- and fast-growing organoids (Figure 2A, B) and then evaluated the metrics experimentally across 10 pancreatic cancer organoid models treated with five chemotherapeutics (Figure 2C, D).

    Figure 2. Comparison of growth-rate-based drug-response metrics across pancreatic cancer organoids. Simulated GR, NDR, and NOGR responses in fast-growing (A) and slow-growing (B) organoids. Experimental comparison of NOGR with GR (C) and NDR (D) across 10 pancreatic cancer organoid models treated with five chemotherapeutics for 72 hours. Each point represents a unique combination of organoid, compound, and concentration. Image adapted from Figure 4 of Deben et al. (2024).

    3. Measuring cytostatic and cytotoxic drug response with NOGR

    NOGR provides a standardized scale from −1 to 1 to quantify organoid drug responses:

    NOGR Value and Interpretation
    NOGR value
    Cytotoxic (NOGR from −1 to 0)Loss of viable organoid area
    Cytostatic (NOGR from 0 to 1)Partial growth inhibition
    −1Cytotoxic response equivalent to the positive control
    0Complete growth arrest
    1Normal growth, equivalent to untreated controls
    The NOGR scale: values above 0 indicate growth inhibition; values below 0 indicate cell death.

    By distinguishing growth inhibition from cell death, NOGR enables researchers to quantify not only drug potency but also the nature and magnitude of treatment responses. Importantly, NOGR uses each well's initial viable organoid area as its baseline, accounting for differences in seeding density and reducing experimental variability. Longitudinal measurements further allow researchers to track how treatment responses change over time.

    NOGR can be calculated entirely from brightfield images using the Orbits platform. AI-powered image analysis identifies viable and dead organoids without fluorescent dyes, enabling repeated measurements from the same wells without destructive assays.

    In our recent application note, our fully label-free Orbits 2.0 models reproduced the NOGR dose response curves obtained using fluorescence-assisted Orbits 1.0 models across four organoid models and two compounds (Figure 3A). NOGR50 values also showed strong agreement between methods (r = 0.99; Figure 3B).

    By combining growth-rate normalization with label-free viability assessment, Orbits enables researchers to quantify cytostatic and cytotoxic drug responses directly from brightfield images. This provides a more comprehensive characterization of treatment effects while supporting non-destructive, longitudinal analysis in high-throughput organoid screening workflows.

    Figure 3. Label-free NOGR quantification distinguishes cytostatic and cytotoxic drug responses. (A) Dose-response curves for four organoid models treated with two compounds, comparing fluorescence-stained Orbits 1.0 models with fully label-free Orbits 2.0 models. (B) Both methods produced comparable dose-response profiles and NOGR50 values (r = 0.99). Abbreviations: PDAC, pancreatic ductal adenocarcinoma; CRC, colorectal cancer; LU, normal lung; CCA, cholangiocarcinoma. Image adapted from Orbits Oncology Application Note AN-01.

    Improve reliability of your organoid drug response analysis

    Accurate organoid drug screening requires metrics that account for differences in growth rate and distinguish growth inhibition from cell death. While GR and NDR address important limitations of conventional viability measurements like RV, neither fully captures these effects across organoid models with different growth characteristics.

    NOGR addresses these limitations by normalizing responses to each well’s seeding density, baseline growth, and appropriate controls, enabling more consistent comparisons across organoid models. Through the Orbits platform, researchers can calculate NOGR directly from brightfield images, enabling automated, label-free, longitudinal analysis without additional staining or destructive assays.

    Already collecting brightfield images of your organoids? Discover how the Orbits platform can help you quantify drug responses using NOGR and uncover deeper insights into treatment response.

    Get in touch

    Sources

    1. Deben, C., et al. Development and validation of the Normalized Organoid Growth Rate (NOGR) metric in brightfield imaging-based assays. Commun Biol 7, 1612 (2024). https://doi.org/10.1038/s42003-024-07329-5
    2. Le Compte, M., et al. Single-organoid analysis reveals clinically relevant treatment-resistant and invasive subclones in pancreatic cancer. npj Precis Oncol 7, 128 (2023). https://doi.org/10.1038/s41698-023-00480-y
    3. Hafner, M., et al. Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs. Nat Methods 13, 521–527 (2016). https://doi.org/10.1038/nmeth.3853
    4. Gupta, A., et al. A normalized drug response metric improves accuracy and consistency of anticancer drug sensitivity quantification in cell-based screening. Commun Biol 3, 42 (2020). https://doi.org/10.1038/s42003-020-0765-z
    5. Orbits Oncology. Retire the lysis step. Label-free organoid viability that outperforms CellTiter-Glo 3D. Application Note AN-01 (2026). https://www.orbits-oncology.com/application-notes/an-01-orbits-vs-celltiter-glo-3d.html